Human blood platelets are important in the functioning of the normal hemostatic mechanism. In addition, they are suspected of playing a central role in the development of arteriosclerosis and other cardiovascular diseases. As they perform their functions, platelets undergo dramatic changes in shape. When exposed to damaged blood vessels, for example, long pseudopods extend from the cell within seconds. At the same time, the platelets adhere to each other and to the vessel wall. These pseudopods can then be retracted, and appear to be responsible for the platelet's ability to generate contractile force. Polymerization and depolymerization of actin filaments is thought to play an important role in these shape changes and force generation. The long term goal of this project is to develop an understanding of how these cycles of polymerization and depolymerization are controlled. We have recently studied a protein preparation from muscle which has the ability to interact specifically with the morphologically defined """"""""pointed"""""""" end of the actin filament in a way that inhibits polymerization at that end. Other investigators have described a protein called acumentin from leukocytes which appears to have similar activity. The immediate goal of this study will be to determine the role these proteins play in the control of actin polymerization. This will be accomplished by further purifying the pointed end inhibitor and examining platelet extracts for proteins which are cross-reactive with the muscle and leukocyte proteins. Attempts will also be made to identify pointed end inhibitor activity in platelets by the same protein purification procedures that were successful in identifying the pointed end inhibitor from muscle. The platelet proteins would then be compared in detail to the muscle and leukocyte inhibitors by a variety of biochemical and functional parameters. The molecular mechanisms of the pointed end capping proteins will also be explored using biophysical techniques such as light acattering, fluorescent energy transfer, and scanning transmission electron microscopy. The possibility that these proteins are regulated by factors such as pH, calcium, and phosphorylation will also be investigated. Studies of highly selected patients with possible abnormalities of platelet structure and contractile function will also be considered. These studies should contribute to our understanding of the physiology of human blood platelets, and provide insight into principles applicable to the field of muscle and nonmuscle motility in general.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL001341-04
Application #
3081760
Study Section
(SRC)
Project Start
1984-07-01
Project End
1989-06-30
Budget Start
1987-07-01
Budget End
1988-06-30
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wilson, Sean R; Sabatine, Marc S; Wiviott, Stephen D et al. (2011) Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR Am Heart J 161:1147-55.e1
Sabatine, Marc S; Morrow, David A; de Lemos, James A et al. (2009) Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 30:162-9
Morrow, David A; Sabatine, Marc S; Brennan, Marie-Luise et al. (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29:1096-102
Mega, Jessica L; Morrow, David A; de Lemos, James A et al. (2008) Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 51:2422-9
Sabatine, Marc S; Morrow, David A; Higgins, Luke J et al. (2008) Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117:1936-44
O'Donoghue, Michelle; Boden, William E; Braunwald, Eugene et al. (2008) Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 300:71-80
Morrow, David A; Wang, Yunmei; Croce, Kevin et al. (2008) Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial Am Heart J 155:49-55
O'Donoghue, Michelle; Morrow, David A; Cannon, Christopher P et al. (2008) Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J 29:984-91
Sabatine, Marc S; Morrow, David A; O'Donoghue, Michelle et al. (2007) Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 27:2463-9
Ray, Kausik K; Morrow, David A; Shui, Amy et al. (2006) Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol 98:861-5

Showing the most recent 10 out of 22 publications